Assessment of the response to imatinib in chronic myeloid leukemia patients–comparison between the FISH, multiplex and RT‐PCR methods
P Raanani, I Ben‐Bassat, S Gan… - European journal of …, 2004 - Wiley Online Library
Objective: The objective of this study was to evaluate the kinetics of molecular response in
chronic myeloid leukemia (CML) patients treated with imatinib and to compare between the …
chronic myeloid leukemia (CML) patients treated with imatinib and to compare between the …
Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of …
TP Hughes, S Branford, J Reynolds, R Koelmeyer… - Blood, 2005 - Elsevier
We have conducted a Phase II trial (TIDEL) in de-novo CML patients using imatinib 600 mg
initially, increasing to 800 mg if specified response criteria were not met, including: major …
initially, increasing to 800 mg if specified response criteria were not met, including: major …
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic …
RD Press, C Galderisi, R Yang, C Rempfer… - Clinical Cancer …, 2007 - AACR
Purpose: Imatinib induces a complete cytogenetic response (CCR) in most chronic myeloid
leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients …
leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients …
Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia
A Burchert, MC Müller, P Kostrewa, P Erben… - Journal of Clinical …, 2010 - ascopubs.org
Purpose Imatinib induces sustained remissions in patients with chronic myelogenous
leukemia (CML), but fails to eradicate CML stem cells. This is of major concern regarding the …
leukemia (CML), but fails to eradicate CML stem cells. This is of major concern regarding the …
Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment
M Colombat, MP Fort, C Chollet, G Marit… - …, 2006 - haematologica.org
BACKGROUND AND OBJECTIVES: Imatinib mesylate induces a complete cytogenetic
response (CCR) in many patients with chronic myeloid leukemia (CML). However, the …
response (CCR) in many patients with chronic myeloid leukemia (CML). However, the …
Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
We conducted a trial in 103 patients with newly diagnosed chronic phase chronic myeloid
leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for …
leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for …
The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia
L Wang, K Pearson, JE Ferguson… - British journal of …, 2003 - Wiley Online Library
Real‐time quantitative reverse transcription‐polymerase chain reaction (Q‐RT‐PCR) is
increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral …
increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral …
The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, and any …
DDM Ross, A Grigg, A Schwarer, C Arthur, K Loftus… - Blood, 2008 - Elsevier
After 5 years of imatinib treatment 40–50% of chronic myeloid leukaemia (CML) patients will
have stable undetectable BCR-ABL by real-time quantitative RT-PCR (RQ-PCR) using strict …
have stable undetectable BCR-ABL by real-time quantitative RT-PCR (RQ-PCR) using strict …
Standardized definitions of molecular response in chronic myeloid leukemia
Abstract The International Randomized Study of Interferon and STI571 (IRIS) demonstrated
long-term cytogenetic responses in patients with chronic-phase chronic myeloid leukemia …
long-term cytogenetic responses in patients with chronic-phase chronic myeloid leukemia …
Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical …
G Martinelli, I Iacobucci, S Soverini… - Hematological …, 2006 - Wiley Online Library
Imatinib mesylate, binding to the inactive conformation of Bcr‐Abl tyrosine kinase and
suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic …
suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic …